Demographic and disease characteristics of the study groups
. | . | HLA class I disparity n = 137 . | . | . | |
|---|---|---|---|---|---|
. | HLA class I identity n = 237 . | KIR ligand compatible n = 89 . | KIR ligand incompatible n = 48 . | P . | |
| Median patient age, y (range) | 42 (16-63) | 38 (17-56) | 37 (21-58) | < .004 | |
| Median donor age, y (range) | 38 (12-66) | 38 (14-71) | 35 (9-63) | NS | |
| Donor source, no. (%) | |||||
| HLA-identical related | 101 (43) | - | - | - | |
| HLA-identical unrelated | 136 (57) | - | - | - | |
| HLA class I-disparate related | - | 31 (35) | 17 (35) | - | |
| HLA class I-disparate unrelated | - | 58 (65) | 31 (65) | - | |
| No. of HLA class I allele disparities (%) | |||||
| 1 | - | 79 (89) | 42 (87) | - | |
| 2-3 | - | 10 (11) | 6 (13) | - | |
| Direction of HLA class I allele disparity, no. (%) | |||||
| Graft-vs-host unidirectional | - | 25 (28) | 0 | - | |
| Graft-vs-host and host-vs-graft | - | 64 (72) | 48 (100) | - | |
| No. female-to-male transplantations (%) | 34 (14) | 19 (21) | 7 (15) | NS | |
| Graft type, no. (%) | NS | ||||
| Marrow | 75 (32) | 39 (44) | 14 (29) | - | |
| Blood stem cells | 162 (68) | 50 (56) | 34 (71) | - | |
| Median nucleated cell dose, × 108/kg (range) | 7.1 (2.1-16.4) | 6.8 (1.7-14.8) | 7.6 (1.4-13.7) | NS | |
| Underlying disease, no. (%) | NS | ||||
| AML/MDS | 88 (37) | 31 (35) | 19 (40) | - | |
| CML | 149 (63) | 58 (65) | 29 (60) | - | |
| Disease stage, no. (%) | < .002 | ||||
| AML/MDS early/advanced | 37 (16)/51 (22) | 6 (7)/25 (28) | 3 (6)/16 (33) | - | |
| CML early/advanced | 125 (53)/24 (10) | 41 (46)/17 (19) | 19 (40)/10 (21) | - | |
| Total early/advanced | 162 (68)/75 (32) | 47 (53)/42 (47) | 22 (46)/26 (54) | - | |
| Median time from diagnosis to transplantation, mo (range) | 11 (3-130) | 16 (4-155) | 16 (4-53) | < .0001 | |
. | . | HLA class I disparity n = 137 . | . | . | |
|---|---|---|---|---|---|
. | HLA class I identity n = 237 . | KIR ligand compatible n = 89 . | KIR ligand incompatible n = 48 . | P . | |
| Median patient age, y (range) | 42 (16-63) | 38 (17-56) | 37 (21-58) | < .004 | |
| Median donor age, y (range) | 38 (12-66) | 38 (14-71) | 35 (9-63) | NS | |
| Donor source, no. (%) | |||||
| HLA-identical related | 101 (43) | - | - | - | |
| HLA-identical unrelated | 136 (57) | - | - | - | |
| HLA class I-disparate related | - | 31 (35) | 17 (35) | - | |
| HLA class I-disparate unrelated | - | 58 (65) | 31 (65) | - | |
| No. of HLA class I allele disparities (%) | |||||
| 1 | - | 79 (89) | 42 (87) | - | |
| 2-3 | - | 10 (11) | 6 (13) | - | |
| Direction of HLA class I allele disparity, no. (%) | |||||
| Graft-vs-host unidirectional | - | 25 (28) | 0 | - | |
| Graft-vs-host and host-vs-graft | - | 64 (72) | 48 (100) | - | |
| No. female-to-male transplantations (%) | 34 (14) | 19 (21) | 7 (15) | NS | |
| Graft type, no. (%) | NS | ||||
| Marrow | 75 (32) | 39 (44) | 14 (29) | - | |
| Blood stem cells | 162 (68) | 50 (56) | 34 (71) | - | |
| Median nucleated cell dose, × 108/kg (range) | 7.1 (2.1-16.4) | 6.8 (1.7-14.8) | 7.6 (1.4-13.7) | NS | |
| Underlying disease, no. (%) | NS | ||||
| AML/MDS | 88 (37) | 31 (35) | 19 (40) | - | |
| CML | 149 (63) | 58 (65) | 29 (60) | - | |
| Disease stage, no. (%) | < .002 | ||||
| AML/MDS early/advanced | 37 (16)/51 (22) | 6 (7)/25 (28) | 3 (6)/16 (33) | - | |
| CML early/advanced | 125 (53)/24 (10) | 41 (46)/17 (19) | 19 (40)/10 (21) | - | |
| Total early/advanced | 162 (68)/75 (32) | 47 (53)/42 (47) | 22 (46)/26 (54) | - | |
| Median time from diagnosis to transplantation, mo (range) | 11 (3-130) | 16 (4-155) | 16 (4-53) | < .0001 | |
- indicates not applicable; NS, nonsignificant.